Clinical pharmacokinetics of fibric acid derivatives (Fibrates)

Clinical Pharmacokinetics

Volumn 34, Issue 2, 1998, Pages 155-162

  Miller, David B ^a   Spence, J David ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b Stroke Prevention and Atherosclerosis Research Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BEZAFIBRATE; CIPROFIBRATE; CYCLOSPORIN; CYTOCHROME P450; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLIBENCLAMIDE; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; METFORMIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TOLBUTAMIDE; WARFARIN;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CLOFIBRATE; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MIXED FUNCTION OXYGENASES; PROCETOFEN; WARFARIN;

EID: 0031909536     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834020-00003     Document Type: Article

References (63)

1. Thorp JM, Waring WS. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature 1962; 194: 948-9
2. Patsch JR, Miesenbock G, Hopferweiser T, et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postpradnial state. Arterioscler Throbm 1992; 12: 1336-45
3. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11: 2-14
4. Manninen V, Elo O, Frick H, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-51
5. Steiner G. Triglyceride-rich lipoproteins and atherosclerosis, from fast to feast. Ann Med 1993; 25 (5): 431-5
6. Gronholdt ML, Nordestgaard BG, Nielsen TG, et al. Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. Stroke 1996; 27 (12): 2166-72
7. Vogel RA, Corretti M, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997; 79: 350-4
8. Kesaniemi YA, Grundy SM. Influence of gemfibrozil on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984; 251: 2241-6
9. Nikkila EA, Huttunen JK, Ehnbolm C. Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metabolism 1977; 26: 179-86
10. Nikkila EA, Ylikahri R, Huttunen JK. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and gulcose tolerance in primary by pertriglyceridemia. Proc. R Soc Med 1776; 69 Suppl. 2: 58-63
11. Desager JP, Horsmans Y, Vandenplas C, et al. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis 1996; 124 Suppl.: S65-73
12. Ooi TC, Simo IE, Yakichuk JA. Delayed clearance of postprandial chylomicrons and their remnants in the hypoalphalipoproteinemia and mild hypertriglyceridemia syndrome. Arterioscler Thromb 1992; 12: 1184-90
13. Stewart JM, Packard CJ, Lorimer AR, et al. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinemic subjects. Atherosclerosis 1982; 44: 355-65
14. Vega GL, Grundy SM. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease: effects on metabolism of low-density lipoproteins. JAMA 1985; 253: 2398-403
15. Saku K, Gartside PS, Hynd BA, et al. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985; 75: 1702-12
16. Stolley PD, Zahm SH. Nonhormonal drugs and cancer. Environ Health Perspect 1945; 103 Suppl. 8: 191-6
17. A co-operative trial in the primary prevention of ischaemic heart disease: report from the Committee of Principal Investigators. Br Heart J 1978 Oct; 40 (10): 1069-118
18. Larsen ML, Illingworth DR, O'Malley JP. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia. Atherosclerosis 1994; 106 (2): 235-40
19. Monk JP, Todd PA. Bezafibrate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidemia. Drugs 1987; 33: 539-76
20. Abshagen U, Kosters W, Kaufmann B, et al. Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure. Klin Wochenschrift 1980; 58: 889-96
21. Abshagen U, Bablok W, Koch K, et al. Disposition pharmacokinetics of bezafibrate in man. Eur J Clin Pharmacol 1979; 16: 31-8
22. Shepherd J. The fibrates in clinical practice: focus on micronised fenofibrate. Atherosclerosis 1994; 110: S55-63
23. Ferry N, Bernard N, Pozet N, et al. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate. Br J Clin Pharmacol 1989; 28: 675-81
24. Davison C, Benziger D, Fritz A, et al. Absorption and disposition of 2-[4-(2,2-dichlorocyclopropyl)-phenoxy]-2-methylpropanoic acid. WIN 35.833, in rats, monkeys and men. Drug Metab Dispos 1975; 3: 520-4
25. Gugler R, Shoeman DW, Huffman DH, et al. Pharmacokinetics of drugs in patients with nephrotic syndrome. J Clin Invest 1975; 55: 1182-9
26. Balfour JA, McTavish D, Heel RC. Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990; 40: 260-90
27. Desager JP, Costermans J, Verberckmoes R, et al. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. Nephron 1982; 31: 51-4
28. 14C-fenofibrate in human plasma. Acta Pharmacol Toxicol 1986; 59 Suppl. 5: 167
29. Desager JP, Harvengt C. Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers. Int J Clin Pharmacol Biopharm 1978; 16: 570-4
30. Munoz A, Guichard JP, Reginault P. Micronised fenofibrate. Atherosclerosis 1994; 110: S45-8
31. Hamberger C, Barre J, Zini R, et al. In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: interactions with other drugs. Int J Clin Pharmacol Res 1986; 6: 441-9
32. US pharmacopoeia drug information; Vol. I. Drug information for the health care professional. 12th ed. Rockville (MD): US Pharmacopeial Convention, 1992
33. Vens-Cappell B, Berndt P, Hilgenstock C, et al. Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. II: multiple-dose administration and chronopharmacokinetics. Arzneimittel Forschung 1993; 43: 351-6
34. Vens-Cappell B, Hilgenstock C, Gellert M, et al. Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. I: single-dose administration. Arzneimittel Forschung 1993; 43: 346-50
35. Guichard JP, Levy-Prades Sauron R. A comparison of the bioavailability of standard or micronized formulations of fenofibrate. Curr Ther Res 1993; 54: 610-4
36. Lipidil product monograph. Fournier Pharma Inc., Montreal (Canada), 1990
37. Cook JA, Rajagopalan R, Eldon MA, et al. Effect of time of dosing on the pharmacokinetics of a controlled-release gemfibrozil tablet (Lopid SR). Pharmacol Res 1991; 8 Suppl.: S296
38. Cook JA, Eldon MA, Gibson DM, et al. Gemfibrozil pharmacokinetics after multiple-dose administration of controlled-release (Lopid SR) and conventional (Lopid) tablets. Pharmacol Res 1992; 9 Suppl.: S325
39. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food [see comments in: ACP J Club 1995; 122 (2): 44]. Ann Intern Med 1994; 121 (9): 676-83
40. Todd PA, Ward A. Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia. Drugs 1988; 36: 314-39
41. Ahmad S. Gemfibrozil interaction with warfarin sodium (coumadin). Chest 1990; 98: 1041-2
42. Blum A, Livneh A, Seligmann H. Severe gastrointestinal bleeding induced by a probable hydroxycoumarin-bezafibrate interaction. Isr J Med Sci 1992; 28: 47-9
43. Ferrari C, Romussu M, Testori GP, et al. Effect of short-term clofibrate on glucose metabolism and insulin secretion in patients with mild maturity-onset diabetes mellitus. Biomedicine 1978; 29: 133-6
44. Brown MS, Goldstein JL. Drugs used in the treatment of hyerlipoproteinemias. In: Gilman AG, editor. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon, 1990: 886-9
45. Ahmad S. Gemfibrozil: interaction with glyburide. South Med J 1991; 84: 102
46. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-5
47. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16: 5-13
48. Spence JD, Munoz CE, Hendricks L. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76: 80-3
49. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995; 52 (15): 1639-45
50. Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54-61
51. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311-21
52. Transon C, Leemann T, Vogt N, et al. In vivo inhibition profile of cyctochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 1995; 58 (4): 412-7
53. Kitazawa E, Tamura N, Iwabuchi H, et al. Biotransformation of pravastatin sodium (I): mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium. Biochem Biophys Res Commun 1993; 192: 597-602
54. Spence JD. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther 1997; 61: 395-400
55. Corpier CI, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239-41
56. East C, Alivizatos PA, Grundy SC, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47-8
57. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 664-5
58. Liedholm H, Nordin G. Erythromycin-felodipine interaction. Drug Intell Clin Pharmacol 1991; 25: 1007-8
59. Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995; 333: 628-33
60. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-9
61. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet 1994; 26 (2): 91-8
62. Rau SE, Bend JR, Arnold MO, et al. Grapefruit juice: terfenadine single-dose interaction: magnitude, mechanism, and relevance. Pharmacokinet Drug Dispos 1997; 61: 401-9
63. Bailey DG, Bend JR, Arnold JMO, et al. Erythromycin-felodipine interaction: magnitude, mechanism and comparison with grapefruit juice. Clin Pharmacol Ther 1996 Jul; 60 (1): 25-33